Avoiding the Premature Introduction of Psychedelic Medicines in Alzheimer’s Disease and Related Disorders

Abstract

informed consent to psychedelic-assisted psychotherapy. Johnson, M. W. 2021. Consciousness, religion, and gurus: Pitfalls of psychedelic medicine. ACS Pharmacology & Translational Science 4 (2):578–81. doi:10.1021/acsptsci. 0c00198. Herzberg, G., K. Conour, J. Butler, A. Emerson, L. S. Gillooly, V. Gold, M. Hayes, L. Mix, and E. Sienknecht. 2019. Towards an ethos of equity and inclusion in the psychedelic movement. Chacruna, December 2019. https://chacruna.net/towards-an-ethos-of-equity-andinclusion-in-the-psychedelic-movement/ Jones, G. M. 2023. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. Journal of Psychopharmacology (Oxford, England) 37 (1):61–9. doi: 10.1177/02698811221127304. Noorani, T. 2021. Containment matters: Set and setting in contemporary psychedelic psychiatry. Philosophy, Psychiatry, & Psychology 28 (3):201–16. Noorani, T., A. Garcia-Romeu, T. C. Swift, R. R. Griffiths, and M. W. Johnson. 2018. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology 32 (7):756–69. Paul, L. A. 2014. Transformative experience. New York: OUP Oxford. Peterson, A., E. A. Largent, H. F. Lynch, J. Karlawish, and D. Sisi. 2023. Journeying to Ixtlan: Ethics of psychedelic medicine and research for alzheimer’s disease and related dementias. AJOB Neuroscience 14 (2):107–123. doi:10. 1080/21507740.2022.2148771. Smith, W. R., and D. Sisti. 2021. Ethics and ego dissolution: The case of psilocybin. Journal of Medical Ethics 47 (12): 807–14. Yaden, D. B., B. D. Earp, and R. R. Griffiths. 2022. Ethical issues regarding nonsubjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics: CQ: The International Journal of Healthcare Ethics Committees 31 (4):464–71. doi:10.1017/S096318012200007X. Yaden, D. B., and R. R. Griffiths. 2021. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science 4 (2):568–72. doi:10.1021/acsptsci.0c00194.